lifestyle.californiaconsumerbanking.com

Author: Castle Biosciences, Inc.

Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

May 4, 2026
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

May 3, 2026
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

May 2, 2026
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

April 30, 2026
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

April 30, 2026
Genesis Energy and board member sued in sexual assault case seeking $50 million in damages

March 19, 2026
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

March 11, 2026
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

March 9, 2026